Ignite Creation Date:
2025-12-25 @ 2:21 AM
Ignite Modification Date:
2026-02-24 @ 12:26 AM
Study NCT ID:
NCT03971734
Status:
TERMINATED
Last Update Posted:
2023-10-06
First Post:
2019-05-31
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Determining Dose of Regadenoson Most Likely to Transiently Alter the Integrity of the Blood-Brain Barrier in Patients With High Grade Gliomas
Sponsor:
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2019-12-06
Start Date Type:
ACTUAL
Primary Completion Date:
2022-04-30
Primary Completion Date Type:
ACTUAL
Completion Date:
2023-10-02
Completion Date Type:
ACTUAL
First Submit Date:
2019-05-31
First Submit QC Date:
None
Study First Post Date:
2019-06-03
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-10-04
Last Update Post Date:
2023-10-06
Last Update Post Date Type:
ACTUAL